workshop 6 workshop 6 towards european consensus
play

WORKSHOP 6 WORKSHOP 6 Towards European consensus indications for - PowerPoint PPT Presentation

WORKSHOP 6 WORKSHOP 6 Towards European consensus indications for major Towards European consensus indications for major antibiotic classes: an exercise with the an exercise with the macrolides macrolides antibiotic classes: Objectives


  1. WORKSHOP 6 WORKSHOP 6 Towards European consensus indications for major Towards European consensus indications for major antibiotic classes: an exercise with the an exercise with the macrolides macrolides antibiotic classes: Objectives Objectives • •To establish the basic To establish the basic pharmacokinetic pharmacokinetic properties and safety profile of properties and safety profile of predefined macrolides macrolides. . predefined • •To make an inventory of the intrinsic susceptibilities of pathogenic To make an inventory of the intrinsic susceptibilities of pathogenic organisms towards macrolides macrolides and establish their key and establish their key organisms towards pharmacodynamic pharmacodynamic parameters in relation to potential use parameters in relation to potential use •The basic indications of The basic indications of macrolides macrolides (evidence-based first and second (evidence-based first and second • line) line) •The problem of resistance and rational approaches to redefining the The problem of resistance and rational approaches to redefining the • indications indications • •The EU consensus on the indication of The EU consensus on the indication of macrolides macrolides •General discussion : towards a consensus General discussion : towards a consensus •

  2. WORKSHOP 6 WORKSHOP 6 Towards European consensus indications for major Towards European consensus indications for major antibiotic classes: an exercise with the an exercise with the macrolides macrolides antibiotic classes: Recommendations for future research Recommendations for future research • Internationally harmonized, evidenced-based guidelines/guidances for preclinical and clinical evaluation need to be developed • Resistance surveillance data which are prospective, community based, unselected, denominator and geographically defined • Pharmacodynamic studies in animals and patients should be further developed to form a scientific basis to support dosing recommendations Recommendations for future research projects Recommendations for future research projects in relation to antibiotic use in relation to antibiotic use • More solid information should be generated on correlation between resistance and clinical failures • Rapid diagnostic tests should be developed to support prudent prescribing • Strong support should be provided for documentation of basic properties and safety/efficacy of generic antibiotics • Address the unknown fields such as true intracellular activity of antibiotics

  3. WORKSHOP 6 WORKSHOP 6 Towards European consensus indications for major Towards European consensus indications for major antibiotic classes: antibiotic classes: an exercise with the an exercise with the macrolides macrolides Recommendations for National Health Authorities Recommendations for National Health Authorities • Revisit SPCs for established antibiotics in situations where there is a rapidly changing susceptibility profile which may affect the empirical efficacy. • Take into account newly emerging safety concerns (e g QTc changes) Recommendations for the EU Recommendations for the EU • Set up necessary programmes for improving the quality of collection, collation and access to sensitivity data to support prescribers and guide drug regulation • Promote the standardisation of a European concensus on susceptibility testing • Promote the development of evidence based European guidelines for the managent of common infectious disease problems

  4. WORKSHOP 6 WORKSHOP 6 Towards European consensus indications for major Towards European consensus indications for major antibiotic classes: antibiotic classes: an exercise with the an exercise with the macrolides macrolides Practical Recommendations for the ESAC project Practical Recommendations for the ESAC project For the project steering committee • Develop robust data on antibiotic usage in relation to trends in susceptibility and by indication

  5. WORKSHOP 6 WORKSHOP 6 Towards European consensus indications for major Towards European consensus indications for major antibiotic classes: antibiotic classes: an exercise with the an exercise with the macrolides macrolides Deliverables Deliverables • What are the acceptable basic first line and second line indications (given the existence of alternatives) for each macrolide ? In general • mainly community-managed infections

  6. WORKSHOP 6 WORKSHOP 6 Towards European consensus indications for major Towards European consensus indications for major antibiotic classes: antibiotic classes: an exercise with the an exercise with the macrolides macrolides Indications (1/3) Respiratory tract infections • streptococcal pharyngitis (alternative to penicillin, especially in patients with beta-lactam allergy) • CAP in outpatients with no signs of severity • pertussis • diphtheria Because of the high prevalence of H. influenzae, macrolides should NO LONGER be recommended for the treatment of : • acute exacerbations of chronic bronchitis • sinusitis • otitis media (unless documentation of proven susceptibility of the causative pathogen)

  7. WORKSHOP 6 WORKSHOP 6 Towards European consensus indications for major Towards European consensus indications for major antibiotic classes: antibiotic classes: an exercise with the an exercise with the macrolides macrolides Indications (2/3) Genital tract infections • chancroid • gonococcal urethritis/cervicitis • Chlamydia and non specific urethritis/cervicitis (azithromycin only) • granuloma inguinale Gastro-intestinal tract infections • Helicobacter pylori infections (clarithromycin only) • Campylobacter enteritis Dental infections • periodontitis

  8. WORKSHOP 6 WORKSHOP 6 Towards European consensus indications for major Towards European consensus indications for major antibiotic classes: antibiotic classes: an exercise with the an exercise with the macrolides macrolides Indications (3/3) Uncomplicated skin & soft tissue infections • impetigo (alternative to penicillin, especially in patients with beta-lactam allergy) • erysipelas (alternative to penicillin, especially in patients with beta-lactam allergy) • acne conglobata • furunculosis Ocular infections • conjunctivitis (systemically) Infections in special populations • Mycobacterium avium infections (clarithromycin and azithromycin only) (prophylaxis, treatment [as part of a combination therapy])

  9. WORKSHOP 6 WORKSHOP 6 Towards European consensus indications for major Towards European consensus indications for major antibiotic classes: antibiotic classes: an exercise with the an exercise with the macrolides macrolides How should indications be reconsidered in areas where resistance is demonstrated ? • CAP • Streptococcal pharyngitis • otitis media - proven susceptibility (?) • impetigo • erysipelas • Campylobacter enteritis • gonococcal urethritis/cervicitis Advice should be sought when frequencies of resistance increase significantly in a given geographical area

  10. WORKSHOP 6 WORKSHOP 6 Towards European consensus indications for major Towards European consensus indications for major antibiotic classes: antibiotic classes: an exercise with the an exercise with the macrolides macrolides Deliverables Deliverables • How should resistance practically modify the basic indications of macrolides and can consistent rules be applied ? For each indication local contemporary susceptibility data should be available to guide empirical prescribing for common target pathogens.

  11. WORKSHOP 6 WORKSHOP 6 Towards European consensus indications for major Towards European consensus indications for major antibiotic classes: antibiotic classes: an exercise with the an exercise with the macrolides macrolides Deliverables Deliverables • Working text on the way to harmonise indications for macrolides in Europe • There should be continued data that supports the clinical indications, safety profile and microbiological activity against target pathogens. • Obstacles which prevent the achievement of these goals should be identified and addressed.

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend